Charles H. Nash

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Pat W. Whitworth, Lisette Stork‐Sloots, Femke A. de Snoo et al. · Annals of Surgical Oncology · 2014 · 88 citations · Full text

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

Pat W. Whitworth, Peter D. Beitsch, Angela Mislowsky et al. · Annals of Surgical Oncology · 2016 · 82 citations · Full text

Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy

Charles H. Nash, Stephen E. Jones, Thomas E. Moon et al. · Cancer · 1980 · 52 citations · Full text

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Peter D. Beitsch, Pat W. Whitworth, Paul L. Baron et al. · Annals of Surgical Oncology · 2017 · 43 citations

Her2+ Breast Cancer, Breast Oncology, Oncology +6

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

Paul L. Baron, Peter D. Beitsch, Danielle Boselli et al. · Annals of Surgical Oncology · 2015 · 31 citations · Full text